NCT07254156Not yet recruiting
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
A Prospective, Multicenter, Exploratory Clinical Study Evaluating the Application of Tissue-Agnostic Technology in the Dynamic Monitoring of Minimal Residual Disease in Stage III Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 28 Nov 2025
Brief summary (registry, in English)
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 229 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 24 Nov 2025
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Colorectal cancer
- NCT number
- NCT07254156
What you commit to
- Study type: Observational
- Planned participants: 229
- From 24 Nov 2025 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of any concurrent medical or psychiatric condition, as assessed by the investigator, that may interfere with protocol compliance, study follow-up, or affect short-term survival.
Other illness
- Has a history of other malignant tumors.
Other
- Pregnant and lactating women.
Who the study is looking for
- Age ≥ 18 years.
- Histologically confirmed colorectal cancer.
- Preoperatively assessed as stage III according to the 8th edition UICC/AJCC staging system.
- Deemed eligible for radical resection upon investigator assessment.
- No prior anti-tumor therapy received.
- ECOG PS score 0-1.
- Willing and able to provide signed informed consent for participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.